EPAS1 and nonpapillary renal cell carcinoma: The percent incidence of these markers presented in Figure 1C shows 35% PHD2, no detectable PHD3, 92% of HIF-α (HIF-1α and/or HIF-2α), and 56% of VEGF-A in 88 cases of ccRCC.